Preventing Weight Regain After Glucagon‐Like Peptide‑1 Therapy Discontinuation: A Pilot Randomized Controlled Trial
Obesity Science & Practice · 2026-10 · 12 (5)
DOI: 10.1002/osp4.70194 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Obesity Science & Practice, online erschienen am 07.10.2026. Verfasst von Kelseanna Hollis-Hansen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Food is Medicine Institute Tufts University Friedman School of Nutrition Science and Policy Boston Massachusetts USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Objective
Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are effective treatments for obesity, but discontinuation is common due to cost, insurance coverage limitations, side effects, patient preference, and other factors. Weight regain often occurs rapidly after cessation, yet few evidence‐based strategies exist to support weight maintenance during this transition. This pilot randomized trial examined whether a digital wellness application or medically tailored meals (MTM) could mitigate weight gain during the first 4 months after GLP‐1 cessation.
Methods
In this pilot randomized trial, adults with prior GLP‐1‐induced weight loss were randomized to usual care, wellness application, or MTM at the time of GLP‐1 cessation. Surveys assessed adherence and satisfaction (primary outcome) as well as exploratory outcomes, diet quality, and perceived health. Weight (exploratory) was measured monthly using validated Bluetooth scales.
Results
Participants ( n = 39) were randomized to control ( N = 14), digital wellness application ( N = 12), or MTM ( N = 13) and had a mean baseline BMI 31.4 (SD 6.3) kg/m 2 . Diet quality, perceived health, adherence, and satisfaction did not significantly differ by group, though some estimates suggested possible trends favoring the wellness application. Relative to control, both the wellness application and MTM groups had less total weight gain: Wellness application −7.16% (95% CI: −12.27, −2.04) and MTM −7.17% (−12.20, −2.14).
Conclusions
These findings suggest that structured support may attenuate early weight gain after GLP‐1 cessation. Larger, more diverse trials with longer follow‐up and clinical outcomes are needed to confirm results and clarify mechanisms.
Autor:innen und Institutionen
- Food is Medicine Institute Tufts University Friedman School of Nutrition Science and Policy Boston Massachusetts USA.
- Peter O'Donnell Jr. School of Public Health UT Southwestern Medical Center Dallas Texas USA.
- Division of General Internal Medicine, Department of Medicine Tufts University School of Medicine Tufts University Boston Massachusetts USA.
- Division of Endocrinology, Department of Internal Medicine UT Southwestern Medical Center Dallas Texas USA.
ORCID-Profile: Kelseanna Hollis-Hansen, Alexander Vonderschmidt, Carolyn Haskins, Ryan M Kane, Jaime P Almandoz, Ildiko Lingvay
Förderung
- NIDDK NIH HHS
- National Institutes of Health
Zitieren
APA
Hollis-Hansen, K., Vonderschmidt, A., Haskins, C., Kane, R. M., Almandoz, J. P., & Lingvay, I. (2026). Preventing Weight Regain After Glucagon‐Like Peptide‑1 Therapy Discontinuation: A Pilot Randomized Controlled Trial. Obesity Science & Practice, 12(5). https://doi.org/10.1002/osp4.70194
Vancouver
Hollis-Hansen K, Vonderschmidt A, Haskins C, Kane RM, Almandoz JP, Lingvay I. Preventing Weight Regain After Glucagon‐Like Peptide‑1 Therapy Discontinuation: A Pilot Randomized Controlled Trial. Obesity Science & Practice. 2026;12(5). doi:10.1002/osp4.70194
BibTeX
@article{HollisHansen2026,
author = {Hollis-Hansen, Kelseanna and Vonderschmidt, Alexander and Haskins, Carolyn and Kane, Ryan M and Almandoz, Jaime P and Lingvay, Ildiko},
title = {Preventing Weight Regain After Glucagon‐Like Peptide‑1 Therapy Discontinuation: A Pilot Randomized Controlled Trial},
journal = {Obesity Science & Practice},
year = {2026},
volume = {12},
number = {5},
doi = {10.1002/osp4.70194}
}
EUVIMED